Suppr超能文献

三种 Y 型配体与 PI3Kα 相互作用的结构见解。

Structural insights into the interaction of three Y-shaped ligands with PI3Kα.

机构信息

Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), Zurich 8093, Switzerland.

出版信息

Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2304071120. doi: 10.1073/pnas.2304071120. Epub 2023 Aug 16.

Abstract

Class IA phosphoinositide 3-kinase alpha (PI3Kα) is an important drug target because it is one of the most frequently mutated proteins in human cancers. However, small molecule inhibitors currently on the market or under development have safety concerns due to a lack of selectivity. Therefore, other chemical scaffolds or unique mechanisms of catalytic kinase inhibition are needed. Here, we report the cryo-electron microscopy structures of wild-type PI3Kα, the dimer of p110α and p85α, in complex with three Y-shaped ligands [cpd16 (compound 16), cpd17 (compound 17), and cpd18 (compound 18)] of different affinities and no inhibitory effect on the kinase activity. Unlike ATP-competitive inhibitors, cpd17 adopts a Y-shaped conformation with one arm inserted into a binding pocket formed by R770 and W780 and the other arm lodged in the ATP-binding pocket at an angle that is different from that of the ATP phosphate tail. Such a special interaction induces a conformation of PI3Kα resembling that of the unliganded protein. These observations were confirmed with two isomers (cpd16 and cpd18). Further analysis of these Y-shaped ligands revealed the structural basis of differential binding affinities caused by stereo- or regiochemical modifications. Our results may offer a different direction toward the design of therapeutic agents against PI3Kα.

摘要

I 类磷酸肌醇 3-激酶 α(PI3Kα)是一个重要的药物靶点,因为它是人类癌症中最常发生突变的蛋白质之一。然而,由于缺乏选择性,目前市场上或正在开发的小分子抑制剂存在安全性问题。因此,需要其他化学支架或独特的催化激酶抑制机制。在这里,我们报告了野生型 PI3Kα、p110α 和 p85α 二聚体与三种 Y 型配体(cpd16(化合物 16)、cpd17(化合物 17)和 cpd18(化合物 18))复合物的低温电子显微镜结构,这些配体具有不同的亲和力,对激酶活性没有抑制作用。与 ATP 竞争性抑制剂不同,cpd17 采用 Y 型构象,其中一个臂插入由 R770 和 W780 形成的结合口袋,另一个臂以与 ATP 磷酸酯尾巴不同的角度位于 ATP 结合口袋中。这种特殊的相互作用诱导 PI3Kα 构象类似于无配体的蛋白质。这些观察结果得到了两种异构体(cpd16 和 cpd18)的证实。对这些 Y 型配体的进一步分析揭示了立体或区域化学修饰引起的结合亲和力差异的结构基础。我们的结果可能为设计针对 PI3Kα 的治疗剂提供了一个不同的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e97/10450665/cd15c5324bf0/pnas.2304071120fig01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验